Are we ready to use anti-amyloid therapy in Alzheimer's disease?

Alzheimer’s disease (AD) is the most common neurodegenerative disease. Biomarkers have demonstrated that AD pathology exists over the disease continuum from a stage preceding symptoms over 15-25 years to the progressively more impaired symptomatic states, mild cognitive impairment (MCI), and dementi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brucki, Sonia Maria Dozzi, César-Freitas, Karolina Gouveia, Spera, Raphael Ribeiro, Borges, Conrado Regis, Smid, Jerusa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia - ABNEURO 2022
Materias:
Neurology of Cognitive and Behavioral Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491439/
https://www.ncbi.nlm.nih.gov/pubmed/35976307
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491439/
https://www.ncbi.nlm.nih.gov/pubmed/35976307
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S117

Ejemplares similares